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Vascular dementia is caused by various factors, including increased age, diabetes, hypertension, atherosclerosis, and stroke.
Adiponectin is an adipokine secreted by adipose tissue. Adiponectin is widely known as a regulating factor related to cardiovascular
disease and diabetes. Adiponectin plasma levels decrease with age. Decreased adiponectin increases the risk of cardiovascular
disease and diabetes. Adiponectin improves hypertension and atherosclerosis by acting as a vasodilator and antiatherogenic factor.
Moreover, adiponectin is involved in cognitive dysfunction via modulation of insulin signal transduction in the brain. Case-control
studies demonstrate the association between low adiponectin and increased risk of stroke, hypertension, and diabetes. This review
summarizes the recent findings on the association between risk factors for vascular dementia and adiponectin. To emphasize this
relationship, we will discuss the importance of research regarding the role of adiponectin in vascular dementia.
1. Introduction
Vascular dementia is the second most common type of
dementia, accounting for 15 to 20% of all cases of demen-
tia [1]. It is characterized by cognitive impairment and
cerebrovascular pathologies [2]. According to the World
AlzheimerReport 2011, an estimated 36million peopleworld-
wide were afflicted with dementia. This number is increasing
twofold every 20 years and will likely reach 115 million
people by 2050 [3, 4]. Among the subtypes of dementia,
vascular dementia is important because it results from a
variety of causes, including cerebrovascular dysfunction.
Vascular dementia and cerebrovascular diseases have com-
mon risk factors including hypertension, insulin resistance,
diabetes, obesity, hyperhomocystinemia, and hyperlipidemia
[5–8]. Recent clinical-pathological studies have focused on
cognitive impairment and increased risk of dementia in
patients with cerebrovascular disease [2, 9, 10]. In addition,
vascular dementia is the most severe form of vascular
cognitive impairment (VCI) [2, 11], and it results from
subclinical vascular brain injury and stroke. VCI reflects the
full range of cognitive alterations due to vascular factors [12].
A previous study demonstrates that reducing vascular risk
factors inhibits cognitive decline progression [12]. Type 2
diabetes mellitus (T2DM), a risk factor for vascular demen-
tia, is a heterogeneous metabolic disease characterized by
reduced insulin sensitivity and relative insulin deficiency.
T2DM and dyslipidemia frequently coexist with vascular
dementia [13]. Adiponectin is almost exclusively secreted
by adipocytes, and it appears to act as a modulator of
anti-inflammation and insulin-sensitizer [14]. Adiponectin
has beneficial effects on endothelial cells and affects the
progression of stroke, atherosclerosis, and hypertension [15–
20]. Plasma adiponectin levels are decreased in patients
with cardiovascular disease and several metabolic disorders
[21]. Several studies reported an inverse relationship between
plasma adiponectin and T2DM [22–26]. In this review, we
examine current research regarding the relationship between
risk factors for vascular dementia and adiponectin.
2. Risk Factors for Vascular Dementia
Vascular dementia is regarded as themost severe form of VCI
characterized by the presence of clinical stroke or vascular
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brain injury aswell as cognitive impairment [2, 11, 27]. Several
studies suggest that the risk factors for vascular dementia
are almost identical as the risk factors for VCI. Common
risk factors in both animal models and humans include
hypertension, insulin resistance, hyperlipidemia, hyperho-
mocystinemia, atherosclerosis, and diabetes [28–32]. Age
is also a risk factor for vascular dementia, suggesting that
dementia in patients after the age of 65 increased gradually
[33]. In addition, cerebrovascular dysfunction is a risk factor
because the cerebrovascular function is reduced in patients
with dementia [34–42]. In addition, another study sug-
gests that metabolic syndrome, including insulin resistance,
hypertension, and dyslipidemia, is associated with cognitive
decline, a typical feature of vascular dementia [30]. Figure 1
shows that vascular dementia risk factors include aging,
diabetes, hypertension, atherosclerosis, and stroke (Figure 1).
3. Adiponectin
Adiponectin is one of themost abundant adipokines [43, 44].
It has significant sequence similarities with complement fac-
torC1q, whose protein is termedAcrp30 because it is a 30 kDa
adipocyte complement-related protein [45, 46]. Adiponectin
is the protein produced by adipose’s most abundant gene
transcript 1 (APM1) gene, and APM1 gene is located on chro-
mosome 3q27, a region associated with T2DM and metabolic
syndrome susceptibility [47–50]. Several human genetic
association studies emphasized that hypoadiponectinemia
caused by the single nucleotides polymorphisms (SNPs) in
APM1 gene is important to investigate the role of adiponectin
in a variety of diseases [14, 51–54] including insulin resistance,
T2DM, and metabolic syndrome, such as obesity [55]. In
white French subjects, 2 SNPs in the promoter region of
APM1 gene, SNP 11377 and SNP 11391, were strongly related to
hypoadiponectinemia and T2DM [50]. In white German and
North American subjects, the +276G/T SNP was associated
with obesity and insulin resistance [52, 56]. In Chinese
subjects, the +276G/T SNP was significantly involved in the
coronary heart disease [57]. Adiponectin acts via binding
its receptors, adiponectin receptor type 1 (AdipoR1) and
type 2 (AdipoR2). AdipoR1 has a higher binding affinity
to the globular form of adiponectin, whereas AdipoR2 has
a higher binding affinity to full-length adiponectin [58].
Adiponectin binds to the C-terminal extracellular domain of
AdipoR, and the N-terminal cytoplasmic domain interacts
with APPL1 [59]. Adiponectin receptors are expressed in
liver, hypothalamus, and brain vascular endothelial cells [60–
62]. Adiponectin is associatedwith insulin resistance, obesity,
T2DM, dyslipidemia, and cardiovascular diseases [63–70]. It
is an effective insulin sensitizer [64, 71, 72], and it promotes
peripheral insulin sensitivity [14] and inhibits liver gluco-
neogenesis [73]. Decreases in circulating adiponectin in the
prediabetic state lead to insulin resistance [74]. Adiponectin
activates AMP-activated protein kinase (AMPK), which
activates insulin-independent glucose uptake by muscle,
downregulates gluconeogenic enzymes, and increasesmuscle
fatty acid oxidation [73]. Unlike other adipocyte-derived
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Figure 1: Risk factors for vascular dementia and adiponectin. Vas-
cular dementia risk factors include aging, diabetes, hypertension,
atherosclerosis, and stroke. Adiponectin is related to aging, diabetes,
hypertension, atherosclerosis, and stroke by acting as amodulator or
regulator in various mechanisms. Current researches have reported
the role of adiponectin in diabetes, hypertension, atherosclerosis,
and stroke.
hormones, adiponectin gene expression and plasma con-
centration are inversely associated with body mass index
(BMI) [75]. Reduced plasma adiponectin levels have also
been reported in patients with coronary artery disease [19] as
well as those with increased carotid intima media thickness
[76]. Plasma adiponectin levels are inversely related to the
platelet activation status of patients with cardiovascular risk
factors [20]. Adiponectin suppresses platelet aggregation in
hyperlipidemic rats by reversing the increase in inducible
nitric oxide synthase expression while enhancing endothelial
nitric oxide synthase activation [77, 78]. Current studies have
reported the association between adiponectin and various
diseases because adiponectin has multiple roles in glucose
and lipid metabolisms and vascular system.
4. Adiponectin, Aging, and Diabetes
4.1. Aging, Insulin Signal Transduction, and Adipocytokines.
Recently, the number of elderly patients with dementia
has been increasing rapidly [79]. One epidemiology study
suggests an exponential increase in the incidence of dementia
after the age of 65, doubling roughly every 5 years, such
that greater than 50% of centenarians are expected to suffer
from dementia [33]. Aging induces an oxidative redox shift
by attenuating mitochondrial metabolism and changing gly-
colysismetabolism [80].These alterations initiate a damaging
pathway involving signaling molecules, transcription factors,
and epigenetic transcriptional regulators [80, 81]. Among
several important pathways formaintaining longevity, insulin
sensitivity has been considered a key factor for the healthy
aging phenotype in humans [82, 83] andmice [84, 85]. Several
studies have reported that insulin and insulin growth factor-
1 (IGF-1) receptor regulate the lifespan of mice [86, 87]. In
humans, growth hormone (GH) and IGF-1 deficiencies are
also associated with life expectancy [88]. Insulin sensitivity
normally decreases during aging, and the prevalence of
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metabolic syndrome (MetS) and insulin resistance substan-
tially increases [89, 90]. In elderly persons, decreased insulin
receptor (IR) levels and impaired insulin signaling have
been observed predominantly in the hippocampus cortex
and choroid plexus [81]. Impaired insulin receptor binding
promotes chronic insulin resistance [91]. Muller et al. [92]
reported that IGF-I signaling deteriorated in the brains of
aged mice. This study demonstrated that activation of the
brain IGF-1R/Akt/GSK-3𝛽 pathway was evidently reduced
although older mice have higher brain IGF-1R levels [92].
In humans, insulin sensitivity decreases with aging and the
prevalence of T2DM increases with advancing age [89, 90].
Reduced mitochondrial function contributes to decline in
glucose uptake with advancing age and leads to insulin
resistance [93–97]. IGF-1 concentrations decline with age and
are associated with age-related changes in body composition
by both increasing fat mass and decreasing muscle mass [98–
100]. Aging alters the function and number of adipose cells
which cause alterations in the secretion and function of the
adipocytokines such as leptin and adiponectin [101]. A recent
study demonstrated that cellular senescence of adipose tissue
causes insulin resistance [102]. Considering these evidences,
aging alters the function of adipose cells, and alteration in
secretion of adipocytokines attenuates insulin sensitivity.
4.2. Adiponectin and Insulin Signal Transduction. Insulin
and IRs are ubiquitously expressed in the brain [81, 103]
where insulin can reach levels 10- to 100-fold greater
than in plasma, particularly in the hippocampus, cortex,
hypothalamus, olfactory bulb, and pituitary [81, 104]. IRs
are largely localized in neurons and are less abundant
in glia [103, 105]. Insulin produced by pancreatic 𝛽-cells
is transported by cerebrospinal fluid (CSF) to the brain
where it crosses the blood-brain barrier (BBB) [106, 107].
Similar to IRs, IGF-1Rs are widely distributed in the brain
[107, 108]. Insulin/IGF-1-mediated activation of Akt leads
to GSK-3𝛽 inactivation, which triggers multiple cascades,
including synthesis of proteins involved in neuronal glu-
cose metabolism and antiapoptotic mechanisms [104, 109].
Regarding brain glucose metabolism, recent studies suggest
that changes in circulating insulin levels modulate glucose
transporter (GLUT) expression [110, 111]. Cerebral IRs and
IGF-1Rs are involved in cortical and hippocampal synaptic
plasticity, thereby affecting memory and learning [105, 112].
In brain, insulin contributes to memory function through
regulation of neurotransmitter receptors and synaptic func-
tion [113, 114]. Additionally, insulin signal transduction also
promotes neurite outgrowth and axonal regeneration in the
brain [105, 112, 115]. In the brain, insulin resistance results
from perturbation of insulin signal transduction, causing
systemic hyperglycemia. Decreased insulin and IGF-1 have
been observed in Alzheimer’s disease brain [116, 117]. Also,
decreased insulin receptor substrate (IRS) protein levels
related to insulin resistance [118] are associatedwith cognitive
decline in dementia [119]. Impaired insulin transduction
aggravates features of Alzheimer’s disease including forma-
tion of neurofibrillary tangle caused by the decreasing brain
glucose level and the increase of amyloid 𝛽 aggregation
[104, 106, 118, 120–122]. In addition, insulin resistance
is closely linked with other metabolic symptoms, includ-
ing hypertension and hyperlipidemia [123]. Adiponectin
directly regulates glucose metabolism and insulin sensitiv-
ity. Adiponectin, via activation of AMPK and adiponectin,
stimulates GLUT4 translocation and glucose uptake [124].
Adiponectin receptors activate AMPK, PPAR-𝛼, and p38
MAPK to increase insulin sensitivity [58, 125]. An adaptor
protein, APPL1, binds to adiponectin receptors that acti-
vate the AMPK and p38 MAPK pathways [126]. In addi-
tion, adiponectin decreases insulin resistance by decreasing
triglyceride content in obese mice [127]. Increased tissue
triglyceride content has been reported to interfere with
insulin-stimulated phosphatidylinositol (PI) 3-kinase acti-
vation and subsequent GLUT 4 translocation and glucose
uptake, thus leading to insulin resistance. Adipose tissue
deficiency or lipodystrophy is associated with insulin resis-
tance and metabolic dysregulation [128]. Adiponectin knock-
out mice show impaired insulin secretion, and intravenous
adiponectin injection into C57BL/6 mice induces insulin
secretion [129, 130]. AdipoR1 and 2 double knockout mice
have increased triglyceride levels in the liver and exhibit
insulin resistance and glucose intolerance, suggesting that
AdipoR1 andAdipoR2 regulate lipid and glucose homeostasis
[14, 131]. In conclusion, adiponectin and adiponectin recep-
tors improve insulin resistance by modulating triglyceride
level and impaired insulin signal transduction. Thus, regu-
lation of adiponectin is important impaired insulin signal
transduction to improve and also adiponectinmay contribute
to the improvement of cognitive decline in dementia.
4.3. Adiponectin, Diabetes, and Vascular Dementia. Diabetes
characterized by reduced insulin sensitivity is associated
with thrombosis, myocardial infarction, and cerebrovascular
disease, which can lead to infarctions and white matter
ischemia [132]. Macrovascular disease causes approximately
80% of mortality in patients with T2DM.The risk of vascular
diseases in patients with T2DM is decreased by lowering
the blood pressure of patients with hypertension [133–135].
In addition, diabetes and hypoglycemia are associated with
cognitive impairment [136–138]. Yaffe et al., in a 4-year
prospective study, suggested that older women with impaired
fasting glucose levels performed poorly on cognitive tests
compared to those with normal glycemia [139]. Considering
these associations, diabetes may be regarded as a risk factor
of vascular dementia. Adiponectin levels are elevated in type
I diabetics compared with healthy controls [140]. Several
studies have consistently found that increased adiponectin
levels are associated with reduced risk for T2DM [22, 25, 26].
Hypoadiponectinemia has been considered an underlying
mechanism of insulin resistance in T2DM [141–145]. In cross-
sectional studies, plasma adiponectin concentrations were
significantly lower in patients with diabetes [146]. In a 5-
year follow-up study of 1096 nondiabetics, the association
between adiponectin and T2DM was attenuated after adjust-
ment for homeostatic model assessment of insulin resistance
(HOMA-IR) and was eliminated after adjustment for insulin
sensitivity. These data suggest that the antidiabetic effect of
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Figure 2: Adiponectin improves insulin sensitivity and reduces diabetes and vascular dementia risk. Adiponectin stimulates AMPK
phosphorylation, GLUT4 translocation, and MAPK pathways. Adiponectin also reduces the levels of triglyceride. Consequentially,
adiponectin increases glucose uptake and insulin sensitivity and reduces insulin resistance. In addition, adiponectin improves the cognitive
decline by modulating impaired insulin signal transduction in vascular dementia brain. These mechanisms decrease the risk of diabetes and
vascular dementia. Also, these mechanisms improve the memory dysfunction in dementia. AMPK: AMP-activated kinase, GLUT4: glucose
transporter type 4, and MAPK: mitogen activated protein kinase.
adiponectin is due to insulin sensitization [147]. Adiponectin
predicts against diabetes onset, and diabetic patients always
show lower plasma adiponectin levels compared to the
general population [148]. Thus, adiponectin reduces the risk
of diabetes by regulating insulin signal transduction and
insulin resistance. Suppression of adiponectin aggravates
diabetes as a risk for vascular dementia. Figure 2 shows that
adiponectin stimulates the phosphorylation of AMPK and
GLUT4 translocation and attenuates levels of triglyceride. As
a result, adiponectin enhances glucose uptake and insulin
sensitivity. This indicates that adiponectin reduces the risk of
diabetes and vascular dementia (Figure 2).
5. Adiponectin, Hypertension, and Stroke
5.1. Adiponectin and Hypertension. Hypertension has been
reported as the most common risk factor for stroke world-
wide and has also been gradually recognized as a risk factor
for dementia [149]. Arterial hypertension contributes to
the development and progression of cerebrovascular disease
[150]. Hypertension exposes the cerebral microvasculature to
pulsatile pressure and flow that cause vascular endothelium
and smooth muscle cell tearing [151]. Many cross-sectional
and longitudinal studies have demonstrated that dementia
and VCI are associated with hypertension [152–156]. There-
fore, previous studies suggest that hypertension is the most
important risk factor for cerebral vessel dysfunction, and
it contributes to cognitive decline [157, 158]. Pulse pressure
(PP), a marker of arterial stiffness, has been connected with
the risk of cognitive decline [159] and AD [160, 161]. Elevated
pulse pressure increases the risk of cognitive decline and
impaired language abilities [162]. Decreased blood pressure
(BP) is a clinical manifestation of dementia in elderly subjects
[163, 164]. Endothelial nitric oxide synthase (eNOS) and
nitric oxide (NO) are crucial regulators of vascular home-
ostasis and, in particular, endothelial function [165, 166].
Endothelium-derived NO is a beneficial factor that pro-
motes vasodilation and inhibits platelet aggregation, mono-
cyte adhesion, and smooth muscle cell proliferation [167].
Adiponectin, acting via AdipoR1 and AdipoR2, promotes
NOproduction throughAMPK signaling pathway activation.
AMPK activates eNOS through phosphorylation at Ser1177
and facilitates complex formation between eNOS and heat
shock protein 90 (HSP-90), which is required for eNOS
activation [167]. Adiponectin knockout mice have reduced
endothelial NO levels in vessel walls [168]. Adiponectin
inhibits the inflammatory response and causes vasodilata-
tion largely through AMPK/eNOS [169–172]. Adiponectin-
induced AMPK signaling promotes phosphatidylinositol 3-
kinase-Akt signaling, leading to angiogenic growth fac-
tor synthesis [170, 173]. A recent study also suggests that
adiponectin inhibits vascular endothelial growth factor-
(VEGF-) induced ROS generation and has an antioxidant
role in the vasculature [174]. These actions of adiponectin
are also mediated via inhibition of growth factor-stimulated
extracellular signal regulated kinase (ERK) signaling. In
addition, several studies indicate that adiponectin plays a
role in the regulation of microvascular network flow and
function [175, 176]. Some clinical research demonstrates that
plasma adiponectin levels are positively associated with arte-
rial vasodilation [177]. Considering the role of adiponectin
in vascular function, decreased adiponectin raises the risk
of hypertension. Figure 3 shows that adiponectin increases
AMPK phosphorylation and NO production. Platelet aggre-
gation is decreased and vasodilation is increased due to
NO production. Finally, adiponectin decreases the risk of
hypertension and improves vascular cognitive impairment
(Figure 3).
5.2. Adiponectin and Atherosclerosis. Atherosclerosis is a
degenerative vessel disease that frequently affects large- to
medium-sized arteries. In the brain, vessels of the circle of
Willis are often involved [178]. Atherosclerotic plaques are
prone to rupture with subsequent thrombosis [179, 180].
The thrombus resulting from plaque rupture leads to vessel
occlusion or embolizes a smaller artery [181]. Atheroscle-
rosis plaque rupture is related to inflammation, includ-
ing secretion of cytokines and matrix-metalloproteinases,
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Figure 3: Adiponectin improves vascular cognitive impairment by stimulating NO production. Adiponectin, acting via AdipoR1 and
AdipoR2, promotes AMPK phosphorylation and NO production. Increased NO reduces platelet aggregation and increases vasodilation.
Consequentially, adiponectin decreases the risk of hypertension and improves vascular cognitive impairment. AMPK: AMP-activated kinase
and NO: nitric oxide.
which are involved in vessel wall degradation [182–186].
Adiponectin plays the role of an antiatherogenic and anti-
inflammatory modulator [18]. Several studies suggest that
adiponectin inhibits many peptides and cytokines related
to atherosclerosis progression [187]. Adiponectin inhibits
monocyte adherence to TNF-𝛼-stimulated endothelial cells
by suppressing adhesion molecule expression [188, 189].
Adiponectin directly inhibits atherogenic molecules, such as
intracellular adhesion molecule-1, vascular cellular adhesion
molecule-1, and E-selectin, which are molecules associated
with heightened leukocyte trafficking [189]. Adiponectin also
attenuates expression of class A scavenger receptor in human
macrophages and inhibits transformation of macrophages to
foam cells [190]. The association between adiponectin and
atherogenic factors indicates that regulation of adiponectin
is important in atherosclerosis.
5.3. Adiponectin and Stroke. Several studies reported that
stroke doubles the risk for dementia (poststroke dementia),
and approximately 30% of stroke patients develop cognitive
dysfunction within 3 years [191–194]. An association between
stroke and dementia is also observed in patients younger
than 50 years, and up to 50% of these patients exhibit
cognitive deficits after a decade [195]. One of the first
population-based studies to assess the relationship between
stroke and dementia was conducted in Rochester, Minnesota
[196]. Many stroke patients show gradual but continuous
deterioration after a single-stroke lesion. This deterioration
is characterized clinically by cognitive and behavioral dys-
function [197]. Several cross-sectional and retrospective case-
control studies have reported an association between low
adiponectin levels and increased stroke risk [16, 198–201].
In addition, adiponectin levels are associated with coro-
nary heart disease such as coronary vascular disease [202,
203]. Several studies demonstrate that hypoadiponectinemia
increases the prevalence of coronary vascular disease [189,
204]. Several studies demonstrated that adiponectin knock-
out (APN-KO) mice showed severe injuries during cerebral
ischemia-reperfusion [205, 206], while adiponectin injected
APN-KO mice were reduced pathological ischemia-induced
damage [207]. Adiponectin blocks the interaction between
the endothelial cells and leukocytes in ischemia-reperfusion
and also inhibits the secondary inflammation in cerebral
ischemia-reperfusion [208]. Adiponectin reduced the infarct
size through nitric oxide synthase dependent mechanism in
cerebral ischemic stroke mice model [209, 210]. In addition,
adiponectin activates AMPK phosphorylation in cerebral
ischemic stroke mice model [211]. Then, the activation of
VEGF by the activated AMPK signaling promotes angiogen-
esis in cerebral ischemic brain [212, 213]. Considering the
results of the above studies, adiponectin is associated with
the risk of stroke and reduces cerebral ischemia induced
damage. This may be due to the roles of adiponectin as
an antiatherogenic modulator and a vasodilator in vascular
system. Figure 4 shows that adiponectin decreases the expres-
sion of atherogenic molecules and plaque formation in blood
vessels. Consequentially, adiponectin attenuates the risk of
stroke and vascular dementia (Figure 4).
6. Conclusions
Risk factors for vascular dementia include advanced age, dia-
betes, hypertension, atherosclerosis, and stroke. Adiponectin,
an adipokine, acts as an antidiabetic and antiatherogenic
regulator. Insulin sensitivity is a key cellular mechanism
related to diabetes, cerebrovascular dysfunction, and cogni-
tive decline. Adiponectin is involved in insulin sensitivity,
and increased adiponectin levels improve impaired insulin
signaling. Moreover, adiponectin affects the cerebrovascu-
lar function by stimulating NO production and inhibiting
transformation of macrophages to foam cells. Specifically, we
summarize the findings as follows.
(1) Vascular dementia characterized by cognitive decline
is associated with increased age because insulin
receptors, which are related to cognitive function,
decrease with age. Adiponectin is associated with
age-related diseases, including cardiovascular disease
and metabolic disease. Adiponectin is mediated via
the activation of AMPK, and adiponectin stimulates
GLUT4 translocation and glucose uptake. Moreover,
binding between adiponectin and adiponectin
receptors activates AMPK, PPAR-𝛼, and p38 MAPK
to increase insulin sensitivity. In addition, in clinical
studies, an association between decreased adiponect-
in and diabetes was demonstrated. In conclusion,
adiponectin improves impaired insulin signaling
and improves cognitive decline as a typical feature of
vascular dementia.
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Figure 4:Adiponectin attenuates the risk of stroke and vascular dementia. Adiponectin decreases the expression of atherogenicmolecules and
formation of form cells in blood vessels. Adiponectin attenuates the risk of stroke by decreasing plaque formation in blood vessels. In addition,
adiponectin binds with AdipoR1 andAdipoR2 and then activates the phosphorylation of AMPK. IncreasedAMPKphosphorylation promotes
the activation of VEGF and NO synthase mechanism. As a result, adiponectin ameliorates angiogenesis in ischemic brain and reduces infarct
size in ischemic brain. Consequentially, adiponectin decreases the risk of stroke and vascular dementia. AMPK:AMP-activated kinase, VEGF:
vascular endothelial growth factor, and NO: nitric oxide.
(2) Vascular dementia characterized by cerebrovascular
dysfunction is associated with hypertension, athero-
sclerosis, and stroke. Adiponectin stimulates NO
production through the AMPK signaling pathway.
Adiponectin also plays the role of an antiatherogenic
modulator. Adiponectin inhibits atherogenicmolecu-
les and attenuates the transformation of macrophages
to foam cells. In conclusion, adiponectin improves
vascular dysfunction and alleviates the progression
of hypertension, atherosclerosis, and stroke as risk
factors for vascular dementia.
(3) Taken together, adiponectin attenuates the risk of vas-
cular dementia and ameliorates vascular dementia-
related pathologies including cerebrovascular dys-
function and cognitive decline which resulted from
impaired insulin transduction and neuroinflamma-
tion.
In this review, we summarized the current research
regarding the association between risk factors for vascular
dementia and adiponectin. Considering the relationship
between adiponectin and risk factors for vascular demen-
tia including aging, diabetes, hypertension, atherosclerosis,
and stroke, we suggest that further studies are necessary
to examine the role of adiponectin in vascular dementia.
Moreover, we emphasize that the regulation of adiponectin
levels and receptors of adiponectin would be important for
the prevention and treatment of vascular dementia.
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